Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: Vinorelbine
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2015-09-09

Last Posted Date: 2015-09-09

Lead Sponsor: Shandong Cancer Hospital and Institute

Target Recruit Count: 200

Registration Number: NCT02544243

A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

Phase 2

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Bortezomib
Drug: Gemcitabine
Drug: Dexamethasone
Drug: Cisplatin

First Posted Date: 2015-09-04

Last Posted Date: 2017-11-14

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 30

Registration Number: NCT02542111

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Solid Tumors

Interventions: Drug: Cisplatin
Drug: Gemcitabine
Drug: Talazoparib

First Posted Date: 2015-09-01

Last Posted Date: 2016-02-11

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT02537561

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of Head and Neck
Locoregionally Advanced

Interventions: Drug: BYL719
Drug: Cisplatin
Radiation: Intensity modulated radiation therapy (IMRT)

First Posted Date: 2015-09-01

Last Posted Date: 2021-04-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 9

Registration Number: NCT02537223

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Phase 1

Active, not recruiting

Conditions: Recurrent Pleural Malignant Mesothelioma
Unresectable Solid Neoplasm
Refractory Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Advanced Peritoneal Malignant Mesothelioma
Advanced Pleural Malignant Mesothelioma
Recurrent Peritoneal Malignant Mesothelioma

Interventions: Drug: Methoxyamine
Drug: Cisplatin
Drug: Pemetrexed Disodium

First Posted Date: 2015-08-28

Last Posted Date: 2024-11-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT02535312

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Keck Medical Center of USC Pasadena, Pasadena, California, United States

and more 11 locations

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Large Cell Carcinoma AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Large Cell Carcinoma AJCC v7
Stage IV Lung Adenocarcinoma AJCC v7
Stage III Lung Adenocarcinoma AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Stage III Lung Large Cell Carcinoma AJCC v7
Stage IIIA Lung Adenocarcinoma AJCC v7

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Drug: Methoxyamine
Drug: Methoxyamine Hydrochloride
Drug: Pemetrexed
Drug: Pemetrexed Disodium

First Posted Date: 2015-08-28

Last Posted Date: 2022-06-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT02535325

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Belinostat
Drug: Rituximab
Drug: Cisplatin
Drug: Cytarabine
Drug: Dexamethasone
Drug: Ciprofloxacin
Drug: Fluconazole

First Posted Date: 2015-08-25

Last Posted Date: 2016-01-06

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02532192

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: M3814 100 mg
Drug: M3814 200 mg
Drug: M3814 300 mg
Drug: M3814 400 mg
Drug: M3814 50 mg
Radiation: Fractionated RT
Drug: Cisplatin

First Posted Date: 2015-08-06

Last Posted Date: 2024-10-11

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 52

Registration Number: NCT02516813

Locations: 🇳🇴
Research site, Oslo, Norway
🇩🇪
Universitaetsklinikum Schleswig-Holstein - Campus Kiel - Klinik für diagnostische Radiologie, Kiel, Germany
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States

and more 16 locations